Athersys, Inc. (NASDAQ:ATHX) has announced the interim results from intravenous administration of MultiStem cell therapy’s phase 2 study. It was conducted with an objective of treating people who had suffered from an ischemic stroke in the past.
What These Results Demonstrate:
The results of this study demonstrate favorable tolerability and safety for MultiStem that is consistent with the studies conducted in the past. When it comes to the primary and secondary endpoints in the study, the cell therapy conducted by researchers didn’t show any difference for a period of 90 days when compared to placebo.
Even though scientists conducted this research successfully, but still they found that the MultiStem treatment was associated with life-threatening adverse events, lower rates of mortality, pulmonary events and various infections. Apart from this, the posthoc analysis results of this study also revealed that those patients who had received MultiStem treatment during the early stage of treatment had a faster recovery than relatives to patients and placebo. The timing of MultiStem treatment had a significant impact on recovery period patients.
As per the reports, Dr. David Hess presented the summary of these results at European Stroke Organization conference that took place on April 19th in Glasgow, Scotland, United Kingdom. Dr. David Hess is the lead clinical investigator in the study. He is a stroke specialist and works with the Medical College of Georgia at Georgia Regents University as the Chairman of the Department of Neurology.
The management team of Athersys is delighted to receive these positive results and feel that they will have a positive impact on the future research studies. According to one of the spokesmen of the company, these results are evidence of the hard work put in by the team of scientists. They have taken the morale of researchers to a new level and have created a base for the future studies.
